Bristol-Myers Squibb's strong profitability, significant drug growth, and low valuation provide great upside potential. Read ...

Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.

Orencia sales $770M, down 2% y/y; Q1 Yervoy sales $624M, up 9% y/y.Stay Ahead of the Market: Discover outperforming stocks ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates ...

Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been recommended by the National ...

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...